Using AI to improve melanoma detection from 3D skin images
Part of Cancer clinical trials.
This study tests whether an artificial intelligence (AI) system can detect melanoma better by looking at 3D images of your skin. It may help find skin cancers earlier, especially if you have many moles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years old or older
- Have more than 15 moles (nevi)
- Skin type I, II, or III (lighter skin tones that burn easily)
- Must be covered by French social security
- No history of chronic inflammatory skin disease (like severe eczema or psoriasis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an artificial intelligence system designed to spot skin cancer early. You may be able to join if you are an adult with a suspicious skin spot and can give permission to participate.
This study compares two systems that take pictures of your whole skin to find melanoma early. You might qualify if you have a higher risk for melanoma, such as having had melanoma before, many moles, or a strong family history.
This study uses artificial intelligence to help detect melanoma (a type of skin cancer) and predict risk in children, teens, and young adults. Researchers want to see if AI can spot melanoma early and assess risk better.
This study tests a device called Nevisense that helps doctors check if a suspicious skin spot is a type of skin cancer called keratinocyte cancer (including basal cell carcinoma, squamous cell carcinoma, and related conditions like actinic keratosis). If you have a spot that your doctor is unsure about, this tool may help get a clearer answer.
This study tests an artificial intelligence (AI) tool that looks at images of skin “peri-scar” areas to predict how well anti-PD-1 immunotherapy will work. It may help doctors better choose treatment for people with hard-to-operate (inoperable) melanoma or certain skin cancers.
This trial tests a new device (Dermalyser) that estimates how thick a suspected melanoma is by analyzing a dermoscopy image. It may help doctors plan surgery without needing extra procedures.
Hear when a new Naevi trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.